Intellia Therapeutics (NTLA) Other Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Other Non-Current Assets data on file, last reported at $1.1 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 64.82% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 64.82% YoY) and the FY2025 annual result came in at $978000.0, down 74.18% from the prior year.
• Other Non-Current Assets climbed to $1.1 million in Q1 2026 per NTLA's latest filing, from $978000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $4.5 million in Q4 2023 and bottomed at $978000.0 in Q4 2025.
• The 4-year median for Other Non-Current Assets is $3.2 million (2024), against an average of $3.0 million.
• Peak annual rise in Other Non-Current Assets reached 10.58% in 2025, while the deepest fall reached 74.18% in 2025.
• Tracing NTLA's Other Non-Current Assets over 4 years: stood at $4.5 million in 2023, then fell by 16.16% to $3.8 million in 2024, then slumped by 74.18% to $978000.0 in 2025, then grew by 7.57% to $1.1 million in 2026.
• Per Business Quant, the three latest NTLA Other Non-Current Assets figures stand at $1.1 million (Q1 2026), $978000.0 (Q4 2025), and $2.9 million (Q3 2025).

Peer Comparison